Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|HER-2 Protein Overexpression|HER-2 Gene Amplification|HER2 Gene Mutation
Interventions: DRUG: ORM-5029
Sponsor: Orum Therapeutics USA, Inc.